NAS:AKRO (USA) Also Trade In: Germany
Akero Therapeutics Inc $ 31.06 1.17 (3.91%)
Warning! GuruFocus has detected 1 Severe warning sign with AKRO. Click here to check it out.
Avg Vol (1m):
Market Cap $:
Enterprise Value $:
Current and historical daily P/E ratio for AKRO (Akero Therapeutics Inc) from 2019 to Jan 23 2021. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Akero Therapeutics stock (AKRO) PE ratio as of Jan 23 2021 is 0. More Details
Akero Therapeutics PE Ratio (TTM) Historical Data
View and export this data going back to 2019. Start your Free Trial
Akero Therapeutics PE Ratio (TTM) Comparison
|Company||Market Cap(Mil)||PE Ratio (TTM)|
Compare NAS:CDXS NAS:AVRO NAS:KALA NAS:FIXX NYSE:KDMN NAS:GTHX NAS:MTEM NAS:ZIOP NAS:OYST NAS:ADAP OCSE:NOVO B ASX:CSL NAS:VRTX NAS:REGN XKRX:207940 NAS:SGEN NAS:MRNA NAS:ALXN XKRX:068270 NAS:INCY
Address 170 Harbor Way, 3rd Floor, South San Francisco, CA, USA, 94080
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical need. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate AKR-001 is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.